Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports  (1/27/21)
Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSCâ„¢ Study for treatment of hospitalized ICU COVID-19 patients. More >

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports  (1/26/21)
Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen. More >

Telemedicine Firm Partners to Offer Reliq Health's iUGO Care RPM and CCM Platforms
Source: Streetwise Reports  (1/25/21)
iDocsWeb reported it formed a strategic partnership with Reliq Health Technologies to offer that firm's iUGO Remote Patient Monitoring, Chronic Care Management and Behavioral Health solutions platforms to its U.S. customers. More >

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports  (1/25/21)
Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNISâ„¢ (voclosporin) for use in treating adults with active lupus nephritis. More >

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports  (1/22/21)
AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. More >

Healthcare Tech Firm Announces New Multilingual IVR Product
Source: Streetwise Reports  (1/21/21)
Reliq Health Technologies launched a multilingual interactive voice recognition product called iUGO Care IVR and has contracted with a Maryland physician practice to offer the service to patients speaking Russian and English. More >

Imagin Medical Is Bringing Cystoscopy into the 21st Century
Source: Dr. KSS, MD, PhD, for Streetwise Reports  (1/21/21)
Dr. KSS, MD, PhD, editor-in-chief of PubBio.co, profiles a small cap that "is poised to bring to clinic a next-generation of must-have cystoscopy equipment." More >

Biotech Given Go-Ahead to Proceed with Phase 3 COVID-19 Study
Source: Streetwise Reports  (1/20/21)
Algernon Pharmaceuticals reported that it has been granted approval from the Data and Safety Monitoring Board to conduct a Phase 3 Study of Ifenprodil for SARS-CoV-2. More >

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports  (1/20/21)
Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2. More >

Life Sciences Firm Partners with University to Develop Biosynthetic Psilocybin
Source: Streetwise Reports  (1/19/21)
Revive Therapeutics entered into a research agreement with North Carolina State University to develop psilocybin utilizing a natural biosynthesis enzymatic platform. More >

Aclaris Shares Triple in Value on Positive Topline Data from Phase 2a Rheumatoid Arthritis Trial
Source: Streetwise Reports  (1/19/21)
Shares of Aclaris Therapeutics Inc. soared to a new 52-week high after the company reported positive preliminary topline data from its Phase 2a trial of oral ATI-450 for moderate to severe rheumatoid arthritis. More >

Neurosciences Firm Outlines Strategic Priorities for 2021
Source: Streetwise Reports  (1/15/21)
ProMIS Neurosciences discusses its four priority areas in 2021. More >

Avinger Shares Rise 40% on Launch of Image-Guided Device to Diagnose and Treat PAD
Source: Streetwise Reports  (1/15/21)
Shares of Avinger Inc. reached a new 52-week high after the company reported it initiated a full commercial launch of its Tigereyeâ„¢ Image-Guided CTO Crossing Catheter system for diagnosing and treating peripheral artery disease. More >

As Psychedelics Move Mainstream, Small Cap Positions Itself at the Center of the Industry
Source: Streetwise Reports  (1/13/21)
Two year old DELIC Corp. has gotten in on the ground floor of the nascent psychedelic sector. More >

Inari Shares Flow 14% Higher on Triple Digit YoY Growth in Procedures and Revenues
Source: Streetwise Reports  (1/13/21)
Shares of Inari Medical Inc. established a new 52-week high after the company reported that preliminary revenue in Q4/20 increased year-over-year by greater than 140%. More >

Mesoblast Reports Phase 3 Trial Data Showing Substantial Reductions in Cardiac and Stroke Events in CHF Patients
Source: Streetwise Reports  (1/11/21)
Shares of Mesoblast Ltd. traded 36% higher after the company reported positive results from its Phase 3 DREAM-HF study showing that a single dose of rexlemestrocel-L provided very significant decreases in heart attacks, strokes and cardiac death in patients diagnosed with chronic heart failure. More >

A Novel, First-in-Class Blood Clotting Agent Takes Shape as a Bloody Compelling Investment
Source: Dr. KSS, MD, PhD, for Streetwise Reports  (1/11/21)
Private start-up RxMP's safe way to stop bleeding inexpensively is already the envy of bigger players, states Dr. KSS, MD, PhD, editor-in-chief of PubBio.co. Can it go the distance through proof of concept? More >

Pharma Developer Outlines 2021 Clinical Program Initiatives
Source: Streetwise Reports  (1/8/21)
Algernon Pharmaceuticals provided an update detailing its plans for 2021 clinical trials. More >

Chimerix Expands Late-Stage Oncology Pipeline Through $78M Oncoceutics Acquisition
Source: Streetwise Reports  (1/8/21)
Chimerix Inc. shares traded 65% higher after the company reported it entered into an agreement to acquire Oncoceutics Inc. in a combination stock and cash deal valued at $78 million plus milestone incentives totaling up to $360 million. More >

Small-Cap Tech Stock Sees Huge Rise; What's Next?
Source: Clive Maund for Streetwise Reports  (1/7/21)
Technical analyst Clive Maund charts Leonovus and discusses what could lie ahead for the stock after it gained 150%. More >

Biopharma's Acute Migraine Trial Yields Positive Efficacy, Safety Results
Source: Streetwise Reports  (1/6/21)
The recently announced topline results from Axsome Therapeutics' MOVEMENT study are reviewed in a Ladenburg Thalmann report. More >

This Tiny Digital Healthcare Company's Sales Should Rocket Higher
Source: Matt Badiali for Streetwise Reports  (1/6/21)
Independent financial analyst Matt Badiali profiles a small cap whose blood glucose monitoring system works with any smartphone. More >

Change Healthcare Shares Surge 30% on $7.8B Merger with UNH's OptumInsight
Source: Streetwise Reports  (1/6/21)
Change Healthcare shares rose to a new 52-week high after the company reported it will be combining its operations with UnitedHealth's OptumInsight in an all cash purchase transaction for $25.75 per share. More >

This Tiny Tech Stock Is Quietly Building a Huge Business in Air Quality
Source: Matt Badiali for Streetwise Reports  (1/5/21)
Independent financial analyst Matt Badiali discusses how mCloud's technology is making it possible for office buildings to reopen during the pandemic. More >

Biopharma Recaps 2020 Accomplishments in COVID-19, Idiopathic Pulmonary Disease
Source: Streetwise Reports  (1/4/21)
Algernon Pharmaceuticals reports that it is aggressively advancing its repurposed drug, Ifenprodil. More >